Furosemide Injection Facing Ongoing Supply Challenges: FDA Shortage Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Furosemide Injection, a cardiovascular medication, due to manufacturing compliance issues. While some suppliers remain available, others report backorders.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Furosemide.
What's in Shortage
Furosemide Injection (Brand Name: FUROSEMIDE) is currently listed in a shortage status by the FDA. This medication is categorized as a cardiovascular therapeutic agent and is primarily supplied in various injection presentations, including 10 mg/1 mL, 20 mg/2 mL, 40 mg/4 mL, and 100 mg/10 mL vials. The shortage was first posted on April 7, 2020, and was most recently updated on February 3, 2026.
Which Manufacturers Are Affected
Availability varies significantly by manufacturer and specific product presentation:
- Accord Healthcare Inc.: All listed presentations are currently Unavailable. (Contact: 866-941-7875)
- Sagent Pharmaceuticals: Reporting Limited availability or Unavailable status. The manufacturer suggests using alternative NDCs (such as NDC 25021-320-02, 25021-320-04, or 25021-320-10) for certain presentations. (Contact: 866-625-1618)
- Eugia US LLC: The 100 mg/10 mL presentation is Available. However, the 20 mg/2 mL and 40 mg/4 mL presentations are Unavailable and on backorder with a recovery date to be determined. (Contact: 888-238-7880)
- Avet Pharmaceuticals, Inc.: Most presentations are Available. One specific presentation (NDC 23155-473-44) is Unavailable with an estimated availability date of March 23, 2026. (Contact: 855-228-9470)
- Fresenius Kabi USA, LLC: Presentations are currently Available. The manufacturer advises checking wholesalers for inventory. (Contact: 888-386-1300)
- Baxter Healthcare: Presentations are currently Available. (Contact: 888-229-0001)
Why There's a Shortage
The FDA notes that the reason for the current shortage is related to requirements for complying with good manufacturing practices.
What Patients Should Do
If you or a loved one relies on Furosemide Injection, please consider the following steps:
- Consult Your Healthcare Provider: Discuss the shortage with your doctor to determine the best course of action for your specific medical needs.
- Speak with Your Pharmacist: Pharmacists often have the most up-to-date information on which specific NDCs are in stock or available through their wholesalers.
- Contact Manufacturers: If you have specific questions regarding the availability of a certain presentation, you may use the contact numbers provided above.
Disclaimer: This article is for informational purposes only. Patients should always consult with their healthcare provider or pharmacist regarding medication changes or medical advice.
Source
FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.